The precursor of resolvin D series and aspirin‐triggered resolvin D1 display anti‐hyperalgesic properties in adjuvant‐induced arthritis in rats
Explore this paper's citation graph
Summary
The possible anti‐hyperalgesic effects of two lipids, aspirin‐triggered resolvin D1 (AT‐RvD1) and its precursor, 17(R)‐hydroxy‐4Z,7Z,10Z,13Z,15E,17R,19Z‐docosahexaenoic acid (17 (R)HDoHE) are investigated.
- Type
- article
- Published
- 2011-09-01
- Cited by
- 213
- References
- 71
- Access
- Open access
- OpenAlex
- https://openalex.org/W1530493878
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:205644258
Keywords
Hyperalgesia, Inflammation, Arthritis, Freund's adjuvant, Pharmacology
References
- Fighting off pain with resolvins
- Lipid mediator class switching during acute inflammation: signals in resolution
- Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant‐induced arthritis in obese and lean rats
- Resolvin D1 controls inflammation initiated by glutathione‐lipid conjugates formed during oxidative stress
- Resolvin D1 attenuates activation of sensory transient receptor potential channels leading to multiple anti‐nociception
- Interleukin-1β-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity
- Lipid mediator interplay: resolvin D1 attenuates inflammation evoked by glutathione‐conjugated lipid peroxidation products
- 15-Deoxy-Δ12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway
- Genetics of osteoarthritis
- Spinal NF‐kB activation induces COX‐2 upregulation and contributes to inflammatory pain hypersensitivity
- Intravenous application of omega-3 fatty acids in patients with active rheumatoid arthritis. The ORA-1 trial. An open pilot study
- Treatment of rheumatoid arthritis: state of the art 2009
- The effects of the selective and non‐peptide CXCR2 receptor antagonist SB225002 on acute and long‐lasting models of nociception in mice
- Role of interleukin-1beta and tumor necrosis factor-alpha-dependent expression of cyclooxygenase-2 mRNA in thermal hyperalgesia induced by chronic inflammation in mice.
- Inflammatory Resolution: new opportunities for drug discovery
- Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
- Resolvin D1 and Its Aspirin-triggered 17R Epimer
- Activation of transcription factors of nuclear factor kappa B, activator protein-1 and octamer factors in hyperalgesia.
- New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases
- A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia
Cited by
- Neutrophils and arthritis: Role in disease and pharmacological perspectives.
- Macrophages: Biology and Role in the Pathology of Diseases
- The search for novel analgesics: targets and mechanisms
- Resolvin D1 protects against hepatic ischemia/reperfusion injury in rats.
- Reversal of IL-13-induced inflammation and Ca(2+) sensitivity by resolvin and MAG-DHA in association with ASA in human bronchi.
- Implications for eicosapentaenoic acid- and docosahexaenoic acid-derived resolvins as therapeutics for arthritis.
- EPA- and DHA-derived resolvins' actions in inflammatory bowel disease.
- 17(R)‐resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception
- Protective Actions of Aspirin-Triggered (17R) Resolvin D1 and its Analogue, 17R-Hydroxy-19-Para-Fluorophenoxy-Resolvin D1 Methyl Ester, in C5a-dependent IgG Immune Complex-Induced Inflammation and Lung Injury
- Resolvins are potent analgesics for arthritic pain
- Roles of resolvins in the resolution of acute inflammation
- Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?
- Aging delays resolution of acute inflammation in mice: reprogramming the host response with novel nanoproresolving medicines
- Antimicrobial aspects of inflammatory resolution in the mucosa: A role for pro-resolving mediators
- Resolution Phase Lipid Mediators of Inflammation: Agonists of Resolution
- Pathways involved in the resolution of inflammatory joint disease.
- Protective effect of apigenin on Freund's complete adjuvant-induced arthritis in rats via inhibiting P2X7/NF-κB pathway.
- Resolution of inflammation: targeting GPCRs that interact with lipids and peptides
- Resolvin D1 and its GPCRs in resolution circuits of inflammation.
- Euphol, a tetracyclic triterpene produces antinociceptive effects in inflammatory and neuropathic pain: the involvement of cannabinoid system.
Related papers
- Modulation of Planaria Regeneration by Resolvin D1 and the Omega-3 Fatty Acid Precursor 17-Hydroxy Docosahexaenoic Acid
- A-317491, a selective P2X3/P2X2/3 receptor antagonist, reverses inflammatory mechanical hyperalgesia through action at peripheral receptors in rats.
- Selective antihyperalgesic effect of [Ser1] histogranin on complete Freund's adjuvant‐induced hyperalgesia in rats
- Inhibition of adjuvant-induced inflammatory hyperalgesia in rats by local injection of neurotrophin-3.
- Antinociceptive activity of the bradykinin B1 and B2 receptor antagonists, des‐Arg9, [Leu8]‐BK and HOE 140, in two models of persistent hyperalgesia in the rat
- Effects of L-NAME on the Mechanical Hyperalgesia after the Development of Inflammation by Freund's Complete Adjuvant in Rat Paw
- A distinct role for transient receptor potential ankyrin 1, in addition to transient receptor potential vanilloid 1, in tumor necrosis factor α-induced inflammatory hyperalgesia and Freund's complete adjuvant-induced monarthritis.
- Electro-acupuncture attenuates behavioral hyperalgesia and selectively reduces spinal Fos protein expression in rats with persistent inflammation.
- The role of peripheral N-methyl-D-aspartate receptors in Freund's complete adjuvant induced mechanical hyperalgesia in rats.
- L-NAME Inhibits Hyperalgesia Induced by Freund's Complete Adjuvant in Rat Paw